Courage Therapeutics is a neuroendocrine therapeutics company translating decades of Dr. Cone’s discoveries and novel chemistries into therapeutic candidates that target the MC4R pathway. Its lead candidate, CTX-B, treats melanocortin-4 receptor haploinsufficiency, and it is a weekly injectable for that indication. Courage’s R&D supports extending the CTX platform into additional therapeutic areas and advances its pipeline through IND-enabling programs toward clinical proof of concept.
MC4R haploinsufficiency is a well-defined genetic obesity affecting patients in the United States with no approved targeted therapeutic options. Courage’s agonists act directly on MC4R to compensate for inadequate ligand expression or to augment endogenous ligand levels and restore pathway activity. In non‑human primates, CTX‑B has shown no cardiovascular signal at supratherapeutic exposures, the liability that suspended some earlier MC4R programs.
Quick Facts
When was Courage Therapeutics' last funding round?
Courage Therapeutics' most recent funding round was for $4.5M (USD) in April 2025.
How much disclosed funding has Courage Therapeutics raised?
As of Apr 30, 2025, Courage Therapeutics has disclosed funding of $5.5M (USD).